Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055185 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
A Phase 2 study, sponsored by Progenics Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00055185: Completed Phase 2 study, sponsored by Progenics Pharmaceuticals.
NCT00055185 is a Phase 2 study that has completed, run by Progenics Pharmaceuticals. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055185, a Phase 2 study, has completed, sponsored by Progenics Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.
Interventions
- DRUG CD4-IgG2 (PRO 542)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-04 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
What the finished NCT00055185 record still lists
NCT00055185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which CD4-IgG2 (PRO 542) is the first listed.
NCT00055185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00055185 about?
NCT00055185 is a clinical study titled "Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients". The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.
What is the current status of trial NCT00055185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2003-04. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00055185?
The interventions under investigation include: CD4-IgG2 (PRO 542) (DRUG).
Who is sponsoring clinical trial NCT00055185?
This trial is sponsored by Progenics Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00055185's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia